NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

On 16 September 2009 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The primary insiders entered into 2 months forward contracts for the purchase of 1,245,000 shares. The transactions made no changes in the net exposure among the insiders. The transactions are described in more detail below. CEO Erik Christensen has entered into a 2 month forward contract for the purchase of 50,000 shares in DiaGenic at NOK 2.71 per share due on 16 November 2009. This contract is a continuation of the forward contract entered into on 18 March 2009 for the same number of shares; a forward contract that today is realised at the price 2.69 per share. Christensen`s exposure in the Company is unchanged at a total of 150,000 shares. Håkon Sæterøy, Executive Chairman of the Board of DiaGenic ASA, has entered into two 2 months forward contracts due on 16 November 2009. The first forward contract is for the purchase of 135,000 shares at NOK 3.22 per share. This contract is a continuation of the forward contract entered into 3 April 2009 for the same number of shares; a forward contract that today was realised at the price 3.20 per share. The second forward contract is for the purchase of 100,000 shares at NOK 2.71 per share. This contract is a continuation of the forward contract entered into 18 March 2009 for the same number of shares; a forward contract that today was realised at the price 2.69 per share. Sæterøy`s overall exposure in the Company is unchanged at a total of 1,376,478 shares. Director and board member Praveen Sharma has entered into two 2 months forward contracts due on 16 November 2009. The first forward contract is for the purchase of 700,000 shares at NOK 3.06 per share. This contract is a continuation of two forward contracts entered into on 16 March 2009 and 3 April 2009 for the same number of shares; forward contracts that today was realised at the price 2.82 per share and 3.20 per share respectively. The second forward contract is for the purchase of 260,000 shares at NOK 2.71 per share. This contract is a continuation of the forward contract entered into 18 March 2009 for the same number of shares; a forward contract that today was realised at the price 2.69 per share. After the transaction Sharma controls a total of 2.995.000 shares in DiaGenic, unchanged by the transaction. Contact: MD PhD Erik Christensen, Managing Director Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com